Systemic Lupus ErythematosusPhase 1NCT02535689
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
A Phase 1 study testing Tofacitinib in people with Systemic Lupus Erythematosus, run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at 1 site in United States.
Trial summary
Background: Systemic lupus erythematosus (lupus) is an autoimmune disease that often involves many systems and organs of the body. Symptoms can include fever, joint pains, and rashes. Serious lupus can also damage organs like the kidneys, lungs, or brain. Drugs used for lupus can have serious side effects. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Systemic Lupus Erythematosus
- What is being tested?
- Tofacitinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 34 participants
- Where
- 1 siteUnited States
- Study dates
- 28 Aug 2015to 26 Apr 2018
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject is capable of providing written informed consent.
- Subject is greater than or equal to 18 years old.
- Meets at least 4 of 11 modified American College of Rheumatology (ACR) (1997) Revised Criteria for the Classification of Systemic Lupus Erythematosus.
- Has mild to moderate disease activity defined as a SLEDAI 2K more than or equal to 2 and less than or equal to 14 at the screening visit.
- If on glucocorticoids, the dose must be less than or equal to 20 mg daily and stable for the 4 weeks prior to screening visit.
- If on hydroxychloroquine or other antimalarials such as chloroquine or quinacrine, the dose must have been stable for the 12 weeks prior to screening visit. The maximum allowed dose is hydroxychloroquine up to 400 mg/day or 6.5 mg/kg/day if more than 400 mg/day. The maximum allowed dose for chloroquine phosphate is up to 500 mg daily and for quinacrine up to100 mg daily.
Show all 9Show fewer
- Males and females with potential for reproduction must agree to practice effective birth control measures. Females should be on adequate contraception if they are of child-bearing potential documented by a clinician, unless patients or spouse have previously undergone a sterilization procedure. Adequate will be considered intrauterine device (IUD) alone or hormone implants, hormone patches, injectables, or oral contraceptives plus a barrier method (male condom, female condom or diaphragm), abstinence or a vasectomized partner
- If patients are on ACE inhibitors or ARB medications, dose of this medication must be stable for 4 weeks prior to study entry.
- Patients may be on lipid lowering medications if initiated at least 6 months prior to the screening visit.
Who cannot join
- Pregnant or lactating women. Women of childbearing potential are required to have a negative pregnancy test at screening.
- Current or prior treatment with rituximab, belimumab or any other biologic agent in the 6 months prior to screening.
- Current treatment with immunosuppressive drugs (methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus). Glucocorticoids are allowed as per the inclusion criteria. At the investigator s discretion, glucocorticoids may be tapered during the study.
- Patients previously on methotrexate, mycophenolate mofetil, cyclosporine or tacrolimus should have stopped it for at least 8 weeks at the time of screening.
- Treatment with cyclophosphamide, pulse methylprednisolone or IVIG within the 6 months prior to screening.
- Increase in glucocorticoid dose within 4 weeks of screening.
Show all 23Show fewer
- A history of drug or alcohol abuse within the 6 months prior to screening.
- History of chronic liver disease or elevated LFTs:
- ALT or AST greater than or equal to 2x upper limit of normal at screening
- serum unconjugated bilirubin > 2mg/dL at screening
- Dialysis or serum creatinine >1.5mg/dL.
- Protein to creatinine ratio of more than 1 mg/mg or 24 hours urine protein of more than 1000 mg.
- Active urinary sediment (WBC, RBC or mixed cellular casts 1+ or more /hpf).
- Hypercholesterolemia: Values after an 8-12 hour fasting blood specimen: total cholesterol >250 mg/dL or LDL >180 mg/dl or hypertriglyceridemia (triglyceride >300 mg/dL) within plus or minus 45 days of screening visit.
- Active infection that requires the use of oral or intravenous antibiotics and has not resolved at least 2 weeks prior to the administration of the first dose of study medication.
- Active chronic infections including but not limited to HIV, Hepatitis B, Hepatitis C, and BK viremia at screening visit.
- History of cancer.
- Known active tuberculosis or untreated latent tuberculosis.
- History of opportunistic infections.
- Subjects with active renal or central nervous system disease or a BILAG A in any organ system.
- WBC <2500/Microlitre or ANC <1,000/Microlitre, Hgb <9.0 g/dL or platelets <70,000/Microlitre or absolute lymphocyte count < 500/Microlitre.
- Current treatment with potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., ketoconazole) or receiving one or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole) that would increase serum availability of tofacitinib. Past treatment with the above mentioned agent is allowed if it was more than a week prior to the administration of the first dose of study medication.
- Significant impairment of major organ function (lung, heart, liver, kidney) or any condition that, in the opinion of the Investigator, would jeopardize the subject s safety following exposure to the study drug.
Trial locations and contacts
1 site in 1 country.
United States1 site
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892
About this study
Official title: Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus; a Phase Ib Clinical Trial and Associated Mechanistic Studies
Background:
Systemic lupus erythematosus (lupus) is an autoimmune disease that often involves many systems and organs of the body. Symptoms can include fever, joint pains, and rashes. Serious lupus can also damage organs like the kidneys, lungs, or brain. Drugs used for lupus can have serious side effects. Also, the drugs don t help some people. Researchers want to find new, more effective and safe treatments.
Read more
Objective:
To evaluate the safety and tolerability of the drug tofacitinib (study drug) in people with lupus.
Eligibility:
People ages 18 and older who have mild to moderate lupus and are not currently or haven t recently had certain lupus treatments.
Design:
Participants will be screened in another protocol.
Participants will have 7 five-hour visits over about 3 months. They will fill out multiple questionnaires. They will have tests, including:
- Physical exam
- Blood and urine tests
- ECG/EKG: Soft electrodes are stuck to the skin to monitor the heart.
- Optional SphygmoCor: Cuffs are attached to the arm and thigh to measure blood pressure and flow speed.
- Optional Endopat: A thimble-shaped cup is placed on the finger to measure blood flow. A cuff is put on the arm to measure blood pressure and flow.
- Optional CAVI: ECG electrodes are placed on both wrists, a microphone placed on the chest, and a blood pressure cuff placed on each arm and leg to measure blood pressure and velocity.
Participants will receive either the study drug or a placebo. They will take this twice a day by mouth for 56 days.
Participants will be contacted by phone 4 times....
Read the detailed description
BACKGROUND:
Systemic Lupus Erythematosus (SLE) is an autoimmune disease with variegated clinical presentation resulting from involvement of multiple biologic pathways. The pathways that lead to loss of tolerance in SLE include: multiple autoreactive cell types (B, T, dendritic, Th17 and regulatory T cells) and abnormal cytokine milieus, genetic factors, environmental and hormonal influences, all of which can influence cell differentiation patterns and reset tolerance checkpoints. In addition, recent studies indicate a putative role for neutrophils in lupus pathogenesis and associated end-organ damage. Currently available therapeutics are frequently inadequate to treat disease flares and simultaneously expose patients to potentially serious toxicities. Further, premature cardiovascular disease not explained by the Framingham risk equation has become one of the most important causes of morbidity and mortality in this patient population. To date, no treatment used in lupus appears to significantly decrease cardiovascular risk. Identifying a drug that has immunomodulatory effects and is also vasculoprotective is an unmet need in this disease.
Tofacitinib is an orally administered Janus kinase (JAK) inhibitor that has recently been approved by the Food and Drug Administration for the treatment of moderate to severe rheumatoid arthritis (RA).
The JAKs are a family of intracellular enzymes (JAK1, 2 and 3 and TYK2) that mediate signaling via a broad range of cytokine receptors. Targeting JAKs is an attractive therapeutic possibility for SLE for many reasons. Many of the inflammatory cytokines implicated in the pathogenesis of SLE signal via the JAK-STAT pathways. JAK inhibitors have been found to have efficacy in various murine models of lupus. Mice treated with a JAK2 inhibitor exhibited reduced serum levels of IL-6, and IL-17 along with reduced numbers of long-lived autoantibody producing plasma cells in the spleen and bone marrow. Furthermore, we have found that administration of tofacitinib reduced serum levels of ANA, IL-6, and IFN-gamma; and ameliorated glomerulonephritis (unpublished data).
This study therefore represents an innovative investigative measure of the safety and efficacy of JAK inhibition in SLE that is predicted by genetic predisposition. We will also investigate effects of tofacitinib on vascular function in SLE subjects and identify biomarkers that may be useful as endpoints in future studies.
PRIMARY OBJECTIVE:
To determine the safety and tolerability of tofacitinib in patients with SLE and mild to moderate disease activity.
STUDY DESIGN:
This is a Phase Ib, randomized, double blind, placebo controlled clinical trial of orally administered tofacitinib, 5 mg twice daily, for the treatment of SLE subjects with mild to moderate disease activity stratified by the presence or absence of STAT4 risk alleles.
- Conditions
- Systemic Lupus Erythematosus
- Being tested
- Tofacitinib, Placebo
- Keywords
- Anti-DNA Antibody, Tofacitinib, Lupus, Safety
- Medical subject headings
- Lupus Erythematosus, Systemic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TofacitinibDrug
Oral administration of tofacitinib, 5 mg
PlaceboDrug
| Study group | Role | What they receive |
|---|---|---|
| 1 | Active comparator | ARM 1: 10 of SLE patients will be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily. Receives: Drug: Tofacitinib |
| 2 | Active comparator | ARM 2: 10 of SLE patients will NOT be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily. Receives: Drug: Tofacitinib |
| 3 | Placebo comparator | ARM 3: 10 of SLE patients will be with variable genotypes will receive placebo twice daily. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary endpoint is safety of tofacitinib in SLE subjects.
Measured: 5 years
Secondary outcomes (2)
Assessments of clinical response.
Assessment of biologic effects.
Measured: 5 years
Assessment of biologic effects.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2015 (estimated)
- Study start28 Aug 2015
- Primary completion26 Apr 2018
- Study completion26 Apr 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Systemic Lupus ErythematosusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Sarfaraz A Hasni, M.D., Principal investigator, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02535689
- Sponsor's protocol ID
- 150185
- Other IDs
- 15-AR-0185
- Status last verified
- 25 Apr 2018
- First submitted
- 28 Aug 2015
- Last updated
- 9 Aug 2018
- Results posted
- No
Publications
O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013 Jan 10;368(2):161-70. doi: 10.1056/NEJMra1202117. No abstract available.
PubMed 23301733O'Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol. 2013 Mar;9(3):173-82. doi: 10.1038/nrrheum.2013.7. Epub 2013 Feb 19.
PubMed 23419429Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7.
PubMed 21383241Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, Wang X, Naqi M, Playford MP, Goel RR, Li X, Biehl AJ, Ochoa-Navas I, Manna Z, Shi Y, Thomas D, Chen J, Biancotto A, Apps R, Cheung F, Kotliarov Y, Babyak AL, Zhou H, Shi R, Stagliano K, Tsai WL, Vian L, Gazaniga N, Giudice V, Lu S, Brooks SR, MacKay M, Gregersen P, Mehta NN, Remaley AT, Diamond B, O'Shea JJ, Gadina M, Kaplan MJ. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021 Jun 7;12(1):3391. doi: 10.1038/s41467-021-23361-z.
PubMed 34099646
Study at a glance
From the registry record, last updated by the sponsor on 9 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus; a Phase Ib Clinical Trial and Associated Mechanistic Studies
- ClinicalTrials.gov ID
- NCT02535689
- Acronym / sponsor ID
- 150185
- Conditions
- Systemic Lupus Erythematosus
- Keywords
- Anti-DNA Antibody, Tofacitinib, Lupus, Safety
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)US National Institutes of Health
- Study start
- 28 Aug 2015
- Primary completion
- 26 Apr 2018 (actual)
- Study completion
- 26 Apr 2018 (actual)
- First posted
- 31 Aug 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
Systemic lupus erythematosus (lupus) is an autoimmune disease that often involves many systems and organs of the body. Symptoms can include fever, joint pains, and rashes. Serious lupus can also damage organs like the kidneys, lungs, or brain. Drugs used for lupus can have serious side effects. Also, the drugs don t help some people. Researchers want to find new, more effective and safe treatments.
Objective:
To evaluate the safety and tolerability of the drug tofacitinib (study drug) in people with lupus.
Eligibility:
People ages 18 and older who have mild to moderate lupus and are not currently or haven t recently had certain lupus treatments.
Design:
Participants will be screened in another protocol.
Participants will have 7 five-hour visits over about 3 months. They will fill out multiple questionnaires. They will have tests, including:
- Physical exam
- Blood and urine tests
- ECG/EKG: Soft electrodes are stuck to the skin to monitor the heart.
- Optional SphygmoCor: Cuffs are attached to the arm and thigh to measure blood pressure and flow speed.
- Optional Endopat: A thimble-shaped cup is placed on the finger to measure blood flow. A cuff is put on the arm to measure blood pressure and flow.
- Optional CAVI: ECG electrodes are placed on both wrists, a microphone placed on the chest, and a blood pressure cuff placed on each arm and leg to measure blood pressure and velocity.
Participants will receive either the study drug or a placebo. They will take this twice a day by mouth for 56 days.
Participants will be contacted by phone 4 times....
Detailed description
BACKGROUND:
Systemic Lupus Erythematosus (SLE) is an autoimmune disease with variegated clinical presentation resulting from involvement of multiple biologic pathways. The pathways that lead to loss of tolerance in SLE include: multiple autoreactive cell types (B, T, dendritic, Th17 and regulatory T cells) and abnormal cytokine milieus, genetic factors, environmental and hormonal influences, all of which can influence cell differentiation patterns and reset tolerance checkpoints. In addition, recent studies indicate a putative role for neutrophils in lupus pathogenesis and associated end-organ damage. Currently available therapeutics are frequently inadequate to treat disease flares and simultaneously expose patients to potentially serious toxicities. Further, premature cardiovascular disease not explained by the Framingham risk equation has become one of the most important causes of morbidity and mortality in this patient population. To date, no treatment used in lupus appears to significantly decrease cardiovascular risk. Identifying a drug that has immunomodulatory effects and is also vasculoprotective is an unmet need in this disease.
Tofacitinib is an orally administered Janus kinase (JAK) inhibitor that has recently been approved by the Food and Drug Administration for the treatment of moderate to severe rheumatoid arthritis (RA).
The JAKs are a family of intracellular enzymes (JAK1, 2 and 3 and TYK2) that mediate signaling via a broad range of cytokine receptors. Targeting JAKs is an attractive therapeutic possibility for SLE for many reasons. Many of the inflammatory cytokines implicated in the pathogenesis of SLE signal via the JAK-STAT pathways. JAK inhibitors have been found to have efficacy in various murine models of lupus. Mice treated with a JAK2 inhibitor exhibited reduced serum levels of IL-6, and IL-17 along with reduced numbers of long-lived autoantibody producing plasma cells in the spleen and bone marrow. Furthermore, we have found that administration of tofacitinib reduced serum levels of ANA, IL-6, and IFN-gamma; and ameliorated glomerulonephritis (unpublished data).
This study therefore represents an innovative investigative measure of the safety and efficacy of JAK inhibition in SLE that is predicted by genetic predisposition. We will also investigate effects of tofacitinib on vascular function in SLE subjects and identify biomarkers that may be useful as endpoints in future studies.
PRIMARY OBJECTIVE:
To determine the safety and tolerability of tofacitinib in patients with SLE and mild to moderate disease activity.
STUDY DESIGN:
This is a Phase Ib, randomized, double blind, placebo controlled clinical trial of orally administered tofacitinib, 5 mg twice daily, for the treatment of SLE subjects with mild to moderate disease activity stratified by the presence or absence of STAT4 risk alleles.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1 | Active comparator | Drug: TofacitinibARM 1: 10 of SLE patients will be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily. |
| 2 | Active comparator | Drug: TofacitinibARM 2: 10 of SLE patients will NOT be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily. |
| 3 | Placebo comparator | Drug: PlaceboARM 3: 10 of SLE patients will be with variable genotypes will receive placebo twice daily. |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Subject is capable of providing written informed consent.
- Subject is greater than or equal to 18 years old.
- Meets at least 4 of 11 modified American College of Rheumatology (ACR) (1997) Revised Criteria for the Classification of Systemic Lupus Erythematosus.
- Has mild to moderate disease activity defined as a SLEDAI 2K more than or equal to 2 and less than or equal to 14 at the screening visit.
- If on glucocorticoids, the dose must be less than or equal to 20 mg daily and stable for the 4 weeks prior to screening visit.
Key exclusion criteria (23 listed)
- Pregnant or lactating women. Women of childbearing potential are required to have a negative pregnancy test at screening.
- Current or prior treatment with rituximab, belimumab or any other biologic agent in the 6 months prior to screening.
- Current treatment with immunosuppressive drugs (methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus). Glucocorticoids are allowed as per the inclusion criteria. At the investigator s discretion, glucocorticoids may be tapered during the study.
- Patients previously on methotrexate, mycophenolate mofetil, cyclosporine or tacrolimus should have stopped it for at least 8 weeks at the time of screening.
- Treatment with cyclophosphamide, pulse methylprednisolone or IVIG within the 6 months prior to screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TofacitinibOral administration of tofacitinib, 5 mg | Drug | 1, 2 |
| Placebo | Drug | 3 |
Primary outcome
The primary endpoint is safety of tofacitinib in SLE subjects.
Time frame: 5 years
2 secondary outcomes
Assessments of clinical response.
Time frame: 5 years
Assessment of biologic effects.
Time frame: 5 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Aug 2018.
- Background: PubMed 23301733O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013 Jan 10;368(2):161-70. doi: 10.1056/NEJMra1202117. No abstract available.
- Background: PubMed 23419429O'Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol. 2013 Mar;9(3):173-82. doi: 10.1038/nrrheum.2013.7. Epub 2013 Feb 19.
- Background: PubMed 21383241Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7.
- Derived from this study: PubMed 34099646Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, Wang X, Naqi M, Playford MP, Goel RR, Li X, Biehl AJ, Ochoa-Navas I, Manna Z, Shi Y, Thomas D, Chen J, Biancotto A, Apps R, Cheung F, Kotliarov Y, Babyak AL, Zhou H, Shi R, Stagliano K, Tsai WL, Vian L, Gazaniga N, Giudice V, Lu S, Brooks SR, MacKay M, Gregersen P, Mehta NN, Remaley AT, Diamond B, O'Shea JJ, Gadina M, Kaplan MJ. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021 Jun 7;12(1):3391. doi: 10.1038/s41467-021-23361-z.
- NIH Clinical Center Detailed Web PageLink provided by the sponsor.
Related trials for Systemic Lupus Erythematosus
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
RecruitingPhase 4
Dapagliflozin in Active Lupus Nephritis
Lupus Nephritis (LN)
RecruitingObservational study
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
RecruitingObservational study
Deciphering the Genetic Architecture of Autoimmune Diseases
Autoimmune Diseases
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sarfaraz A Hasni, M.D. principal investigator
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Tofacitinib in people with Systemic Lupus Erythematosus, run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary endpoint is safety of tofacitinib in SLE subjects. (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02535689, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Aug 2018.